Endometrial Cancer Gene-Edited Cell Lines for Drug Discovery

According to the World Health Organization (WHO) GLOBOCAN 2020, endometrial cancer is the sixth most common cancer in women worldwide, with approximately 417,000 new cases and 97,000 deaths annually. In the United States, the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports an age-adjusted incidence rate of 27.1 per 100,000 women per year (2017-2021). The 5-year relative survival rate is 81% overall but drops sharply from 95% for localized disease to 18% for distant-stage disease. Key risk factors include obesity, unopposed estrogen exposure, diabetes, and Lynch syndrome. The rising incidence, particularly of aggressive subtypes, underscores the urgent need for improved preclinical models.

Endometrial cancer is an ideal model for studying hormone-driven carcinogenesis, PI3K/AKT pathway addiction, and chromatin remodeling defects. The disease is molecularly classified into four subtypes by The Cancer Genome Atlas (TCGA): POLE ultramutated, microsatellite instability hypermutated (MSI), copy-number low (endometrioid), and copy-number high (serous-like). These subtypes exhibit distinct mutational landscapes, clinical outcomes, and therapeutic vulnerabilities. Publicly available datasets from TCGA, cBioPortal, and DepMap provide rich genomic, transcriptomic, and functional dependency data. Open research questions include mechanisms of resistance to hormonal therapy and immune checkpoint inhibitors, and the role of tumor heterogeneity in treatment failure.

Endometrial carcinogenesis involves sequential alterations in several key pathways:

1. PI3K/AKT/mTOR pathway activation:

• • PTEN loss (most frequent early event)
• • PIK3CA activating mutations
• • AKT1 E17K mutations
• • mTOR complex activation

2. WNT/beta-catenin pathway:

• • CTNNB1 exon 3 mutations (stabilizing beta-catenin)
• • Nuclear beta-catenin accumulation
• • Transcriptional activation of MYC and CCND1

3. RAS/MAPK pathway:

• • KRAS activating mutations (codons 12, 13, 61)
• • BRAF V600E (rare)
• • RASA1 loss

4. Chromatin remodeling:

• • ARID1A loss-of-function mutations (SWI/SNF complex)
• • PBRM1, SMARCA4 alterations

The following table summarizes the most frequent genetic alterations in endometrial cancer based on TCGA and COSMIC data:

Key signaling networks driving endometrial cancer include:

• • PI3K/AKT/mTOR network:
• • PTEN loss leads to PIP3 accumulation and AKT activation
• • AKT phosphorylates TSC2, relieving inhibition of mTORC1
• • mTORC1 promotes protein synthesis, cell growth, and proliferation
• • Negative feedback via S6K1 to IRS1 is often disrupted
• • WNT/beta-catenin network:
• • CTNNB1 mutations or loss of APC/axin leads to nuclear beta-catenin
• • Beta-catenin/TCF/LEF transcription factors activate MYC, CCND1, AXIN2
• • Crosstalk with PI3K/AKT via GSK3-beta inactivation
• • RAS/MAPK network:
• • KRAS mutations activate RAF/MEK/ERK cascade
• • ERK phosphorylates transcription factors (ELK1, FOS, JUN)
• • Promotes cyclin D1 expression and cell cycle progression
• • p53 network:
• • TP53 mutations lead to loss of cell cycle arrest and apoptosis
• • Genomic instability and aneuploidy
• • Synergy with PTEN loss in aggressive serous-like tumors

Commonly used endometrial cancer cell lines and their key mutations:

Organoid models derived from patient tumors preserve the mutational landscape and histological architecture. They are increasingly used for drug sensitivity testing and personalized medicine studies. Limitations include lack of stroma and immune microenvironment.

Key animal models for endometrial cancer research:

• • Patient-derived xenografts (PDX):
• • Implantation of patient tumor fragments into immunodeficient mice
• • Retain tumor heterogeneity and mutational profile
• • Useful for preclinical drug testing and biomarker discovery
• • Genetically engineered mouse models (GEMM):
• • Pten conditional knockout (LoxP/LoxP) with Cre under progesterone receptor promoter
• • Pten/Pik3ca double mutant mice develop invasive endometrioid tumors
• • Tp53/Pten double knockout models serous-like disease
• • Induced models:
• • Orthotopic injection of luciferase-labeled cell lines into uterine horn
• • Allows non-invasive monitoring of tumor growth and metastasis
• • Chemically induced models (e.g., MPA + E2) for hormone-driven tumors

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with defined genetic alterations, providing powerful tools for functional genomics and drug discovery. Examples include:

• • TP53 knockout models: Disruption of TP53 in HEC-1A or Ishikawa cells to study p53 loss-of-function and genomic instability.
• • PTEN knockout models: Complete loss of PTEN in RL95-2 or AN3 CA cells to isolate the effects of PTEN loss on PI3K signaling.
• • PIK3CA H1047R knock-in: Introduction of the common activating mutation into PTEN-null cells to model combined PI3K pathway activation.
• • ARID1A knockout: Loss of ARID1A in Ishikawa cells to study chromatin remodeling defects and synthetic lethal interactions.
• • KRAS G12D knock-in: Introduction of the activating mutation into wild-type cells to study MAPK pathway dependency.

Commercially available, sequence-verified isogenic cell lines accelerate research by eliminating the time-consuming process of clone selection and validation. These models are essential for target validation, drug screening, and understanding resistance mechanisms.

Gene-edited cell lines are used to validate candidate driver genes identified from sequencing studies. For example:

• • Knockout of ARID1A in endometrial cancer cell lines leads to increased proliferation and altered chromatin accessibility, confirming its tumor suppressor role.
• • Knock-in of PIK3CA H1047R in PTEN-null cells enhances AKT phosphorylation and cell survival, demonstrating cooperativity between these mutations.
• • TP53 knockout in HEC-1A cells results in resistance to DNA-damaging agents and increased chromosomal instability.
• • CRISPR screens using pooled sgRNA libraries in isogenic backgrounds identify genes essential for growth in the presence or absence of specific mutations.

Isogenic pairs (wild-type vs. gene-edited) enable precise assessment of drug sensitivity:

• • PTEN-null cells show increased sensitivity to PI3K/mTOR inhibitors (e.g., everolimus, taselisib) compared to PTEN wild-type cells.
• • PIK3CA H1047R knock-in cells are more sensitive to PI3K-alpha selective inhibitors (e.g., alpelisib).
• • ARID1A knockout cells exhibit sensitivity to EZH2 inhibitors (e.g., tazemetostat) due to synthetic lethality.
• • Resistance models: Chronic exposure of isogenic cells to a drug can select for resistant clones, which can be sequenced to identify resistance mechanisms (e.g., secondary mutations in the drug target or activation of bypass pathways).

CRISPR-based functional genomics screens in endometrial cancer cell lines identify biomarkers of drug response and synthetic lethal interactions:

• • Genome-wide CRISPR knockout screens in PTEN-null cells identify genes whose loss sensitizes cells to PI3K inhibitors (e.g., FBXW7, TSC1).
• • Screens in ARID1A knockout cells reveal dependencies on the SWI/SNF complex member SMARCA4 and the histone methyltransferase EZH2.
• • Synthetic lethality screens identify vulnerabilities specific to TP53-mutant cells, such as WEE1 and CHK1 inhibitors.
• • These screens can be performed in commercially available isogenic cell lines to ensure reproducibility and reduce confounding genetic background effects.

The following databases provide essential genomic, transcriptomic, and functional data for endometrial cancer research: